Recombinant Technologies
Patented Treatment for Alzheimer's
Company Information
Alzheimer’s affects an estimated 5.5 million people in the U.S.
Recombinant Technologies has developed a treatment that addresses the root cause of this disease, rather than the symptoms.
The company has designed an injection of a molecule that reduces plaque buildup on the brain. According to the company, this buildup is what causes dementia and leads to Alzheimer’s.
Recombinant’s patented technology has been developed over a decade, and funded with $4.5 million in grants from the National Institutes of Health.
The molecule has successfully improved memory in mice, and the company is now ready to move toward human trials. It aims to complete these trials and start the FDA approval process within two to three years.